peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical Announces Appointment of Anne Säfström Lanner as Vice President, Global Human Resources

18 Jan 2019, 08:00
Lund, Sweden, January 18, 2019 -- Hansa Medical AB (NASDAQ Stockholm: HNSA), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced the appointment of Anne Säfström Lanner as Vice President, Global Human Resources.

Mrs. Lanner has over 15 years of broad human resources experience in international growth companies, including developing and implementing strategies for talent acquisition and management, organizational culture and employer branding, compensation and benefits, and employee training and development. Prior to joining Hansa, she served at European Spallation Source (ESS), a European multi-disciplinary research facility, in HR leadership roles of increasing responsibility, most recently as Head of Resourcing. Previously, Mrs. Lanner was Head of Human Resources at CellaVision, a provider of digital solutions for medical microscopy within hematology. She earned her Bachelor of Social Science in Human Resource Management, with a focus in organizational development & leadership, at Lund University.

“We are delighted to welcome Anne as we grow Hansa Medical into a global commercial-stage biopharma company. Anne is very experienced in developing strategic human resources programs aligned with business objectives and will work with management to help maximize Hansa’s organizational productivity and secure our position as an employer of choice,” said Søren Tulstrup, President & CEO of Hansa Medical.

The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on January 18, 2019. 

For further information, please contact:

Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert 
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media)
+1 212 600 1902

About Hansa Medical
Hansa Medical (NASDAQ Stockholm: HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.